quetiapine-fumarate and Weight-Loss

quetiapine-fumarate has been researched along with Weight-Loss* in 6 studies

Trials

2 trial(s) available for quetiapine-fumarate and Weight-Loss

ArticleYear
A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers.
    Addiction biology, 2013, Volume: 18, Issue:6

    Marijuana withdrawal contributes to the high relapse rates in individuals seeking treatment for marijuana-use disorders. Quetiapine, an atypical antipsychotic, reduces characteristic symptoms of marijuana withdrawal in a variety of psychiatric conditions, including mood lability, sleep disruption and anorexia. This human laboratory study investigated the effectiveness of quetiapine to decrease marijuana withdrawal and relapse to marijuana use in non-treatment-seeking marijuana smokers. Volunteers were maintained on placebo or quetiapine (200 mg/day) in this double-blind, counter-balanced, within-subject study consisting of two 15-day medication phases, the last 8 days of which were in-patient. On the first in-patient day, active marijuana [6.2% delta (9)-tetrahydrocannabinol (THC)] was repeatedly smoked under controlled conditions. For the next 3 days, inactive marijuana (0.0% THC) was available for self-administration (withdrawal). On the subsequent 4 days, active marijuana (6.2% THC) was available for self-administration (relapse). Volunteers (n = 14) who smoked an average of 10 marijuana cigarettes/day, 7 days/week, completed the study. Under placebo, withdrawal was marked by increased subjective ratings of negative mood, decreased sleep quality, and decreased caloric intake and weight loss. Compared with placebo, quetiapine improved sleep quality, increased caloric intake and decreased weight loss. However, quetiapine increased marijuana craving and marijuana self-administration during the relapse phase. These data do not suggest that quetiapine shows promise as a potential treatment for marijuana dependence.

    Topics: Adult; Affect; Analysis of Variance; Anorexia; Antipsychotic Agents; Dibenzothiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Female; Humans; Male; Marijuana Abuse; Middle Aged; Neuropsychological Tests; Placebos; Psychomotor Performance; Quetiapine Fumarate; Secondary Prevention; Self Administration; Sleep Wake Disorders; Substance Withdrawal Syndrome; Weight Loss; Young Adult

2013
Weight decline in patients switching from olanzapine to quetiapine.
    Schizophrenia research, 2004, Sep-01, Volume: 70, Issue:1

    This open-label study investigated the strategy of switching patients who had gained excessive weight on olanzapine to quetiapine, with assessments of safety and continued efficacy as well as weight change. Patients who were psychiatrically stable on olanzapine but had gained >20% in weight and had body mass index >25 mg/kg(2) were switched to quetiapine over a 4-week period and followed for 6 weeks, the total study duration being 10 weeks. Assessments included weight change, antipsychotic efficacy using the Positive and Negative Symptom Syndrome Scale (PANSS), extrapyramidal adverse events using the Simpson-Angus Scale (SAS), and laboratory studies for metabolic measures. Of 16 enrolled patients, 12 completed the study. Mean weight loss was 2.25 kg (Cohen's d = 0.12; P = 0.03). There were no significant changes in PANSS total scores, SAS scores, or metabolic parameters. Switching patients to quetiapine, appears to be a viable strategy for managing olanzapine-induced weight gain as indicated by this 10-week open-label study. Prospective controlled trials of longer duration and larger number of subjects are needed.

    Topics: Basal Ganglia Diseases; Benzodiazepines; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Quetiapine Fumarate; Weight Loss

2004

Other Studies

4 other study(ies) available for quetiapine-fumarate and Weight-Loss

ArticleYear
Metformin for weight loss and control in patients with mood disorder.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:10

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Hypoglycemic Agents; Male; Metformin; Mood Disorders; Quetiapine Fumarate; Treatment Outcome; Weight Gain; Weight Loss

2014
Quetiapine-induced insulin resistance after switching from blonanserin despite a loss in both bodyweight and waist circumference.
    Psychiatry and clinical neurosciences, 2012, Volume: 66, Issue:6

    Topics: Antipsychotic Agents; Dibenzothiazepines; Female; Homeostasis; Humans; Insulin Resistance; Piperazines; Piperidines; Quetiapine Fumarate; Schizophrenia; Waist Circumference; Weight Loss; Young Adult

2012
Weight loss and anorexia with quetiapine.
    Psychiatric services (Washington, D.C.), 2005, Volume: 56, Issue:4

    Topics: Aged; Anorexia; Antipsychotic Agents; Dibenzothiazepines; Humans; Male; Quetiapine Fumarate; Schizophrenia; Weight Loss

2005
Reversal of antipsychotic-induced weight gain during quetiapine treatment.
    International clinical psychopharmacology, 2003, Volume: 18, Issue:6

    Weight gain in mentally ill patients is an evident problem, and obesity can be two- to three-fold more prevalent in psychiatric patients than in the general population. We report two patients who gained weight during previous antipsychotic treatment but who lost weight when shifted to quetiapine.

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain Injuries; Chlorpromazine; Dibenzothiazepines; Humans; Male; Obesity; Olanzapine; Quetiapine Fumarate; Schizophrenia, Paranoid; Weight Gain; Weight Loss

2003